Health
Eli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly‘s weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company […]
Read More
Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and […]
Read More
Healthy Returns: Here’s what GLP-1s are being tested for beyond weight loss, diabetes
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The list of potential health benefits from […]
Read More
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over […]
Read More
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, […]
Read More
Lost in the market’s sharp rotation out of tech stocks is a really bullish call on major banks
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market slides : The S & P 500 gave back earlier gains and fell throughout Tuesday afternoon, led lower by the mega-cap tech stocks. Ahead of the […]
Read More
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
Kena Betancur | Corbis News | Getty Images Pfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales. The company now expects to book adjusted earnings of $2.45 to $2.65 […]
Read More
We’re encouraged by Abbott stock trading but discouraged by moves in Honeywell
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market moves: The S & P 500 was on track for small gains following a solid rally last Friday. There’s still some market rotation happening, but […]
Read More
Here are JPMorgan’s top drug stock picks into earnings
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of 2024 have shifted and sparked a rotation out of large technology stocks into less-loved areas of the market, including value stocks and small caps. The […]
Read More
Jim Cramer’s advice on Abbott Labs stock after a nearly $500 million baby formula verdict
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Wall Street was lower after Friday’s rebound in a wild week that featured rotations in and out of tech. It’s a busy week ahead with a Fed meeting, 14 earnings […]
Read More